
Biodexa Pharmaceuticals PLC
NASDAQ:BDRX

Fundamental Analysis


Revenue & Expenses Breakdown
Biodexa Pharmaceuticals PLC
Balance Sheet Decomposition
Biodexa Pharmaceuticals PLC
Current Assets | 8.8m |
Cash & Short-Term Investments | 1.7m |
Receivables | 715k |
Other Current Assets | 6.4m |
Non-Current Assets | 6m |
PP&E | 324k |
Intangibles | 5.6m |
Free Cash Flow Analysis
Biodexa Pharmaceuticals PLC
GBP | |
Free Cash Flow | GBP |
Earnings Waterfall
Biodexa Pharmaceuticals PLC
Revenue
|
0
GBP
|
Operating Expenses
|
-9.2m
GBP
|
Operating Income
|
-9.2m
GBP
|
Other Expenses
|
3.5m
GBP
|
Net Income
|
-5.7m
GBP
|
BDRX Profitability Score
Profitability Due Diligence
Biodexa Pharmaceuticals PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Score
Biodexa Pharmaceuticals PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
BDRX Solvency Score
Solvency Due Diligence
Biodexa Pharmaceuticals PLC's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Score
Biodexa Pharmaceuticals PLC's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BDRX Price Targets Summary
Biodexa Pharmaceuticals PLC
Dividends
Current shareholder yield for BDRX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?